Ashland (ASH) Earnings Date & Reports

Key Takeaways

• Ashland reported fourth-quarter fiscal 2026 revenue of $498 million, up 4% year over year but slightly below the consensus estimate of about $501.8 million.
• The quarter swung to a net loss of $16 million, or $0.35 per diluted share, reflecting asset impairment, restructuring, and Argentina liquidation charges.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose 2% to $121 million, with an adjusted EBITDA margin of 24.3%.
• Adjusted diluted EPS excluding intangibles amortization reached $1.12, up from $1.08 in the prior-year quarter but below analyst expectations.
• Life Sciences delivered a record quarterly adjusted EBITDA margin of 35.6%, while Specialty Additives was held back by lower Hopewell plant productivity.
• Ashland issued fiscal 2027 guidance for revenue of $1.905 billion to $1.975 billion and adjusted EBITDA of $405 million to $435 million.
• For deeper coverage of ASH, explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
• Discover automated trading ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Ashland's fourth-quarter and full-year fiscal 2026 results offer an important checkpoint on the specialty ingredients maker's recovery, following a fiscal 2025 marked by a $706 million goodwill impairment and the Avoca divestiture. The company ended fiscal 2026 with sales of $1.863 billion, up 2%, and returned to a modest full-year net profit of $4 million versus a prior-year net loss of $845 million. For investors, the report matters most for its signal on demand momentum across pharma, personal care, and coatings, as well as progress on the Hopewell productivity investments. The newly issued fiscal 2027 outlook provides the first official read on whether management expects that momentum to continue.

Reported Results

For the fourth quarter ended September 30, 2026, Ashland reported sales of $498 million, a 4% increase from $478 million a year earlier, driven by a 3% volume gain and 2% higher pricing, partially offset by foreign currency. The figure came in just below the consensus estimate of roughly $501.8 million. The company posted a net loss of $16 million, or $0.35 per diluted share, compared with net income of $32 million, or $0.71 per share, in the prior-year quarter. The loss reflected an $18 million asset impairment, a $13 million cumulative translation adjustment tied to the liquidation of its Argentine entity, restructuring and separation costs, and an environmental reserve adjustment.

On an adjusted basis, EBITDA rose 2% to $121 million, and adjusted diluted EPS excluding intangibles amortization increased to $1.12 from $1.08. Segment results were mixed: Life Sciences sales grew 4% to $180 million with adjusted EBITDA up 16%, while Personal Care sales rose 8% to $163 million. Specialty Additives sales were flat at $131 million as lower Hopewell productivity drove a 31% drop in segment adjusted EBITDA.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters spanning industry, market capitalization, technical indicators, price patterns, and performance metrics. The tool is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to see how it can support your own research workflow.

Market Reaction and Investor Sentiment

Investor sentiment heading into the report was cautiously optimistic, with consensus expectations centered on roughly $501.8 million in revenue and adjusted EPS near the low-to-mid $1.20 range. The modest top-line miss and an adjusted EPS result below the Street likely weighed on sentiment, even as the company pointed to a third consecutive quarter of year-over-year sales growth in China and record profitability in Life Sciences. The swing to a reported net loss, driven primarily by non-cash and one-time items, may create near-term headline noise, but the company's strong cash generation—operating cash flow of $385 million for the year—offers a more constructive signal. Post-earnings price behavior will likely hinge on how investors weigh the fiscal 2027 guidance against current estimates.

Forward Outlook and Key Factors to Monitor

Ashland's fiscal 2027 guidance calls for revenue between $1.905 billion and $1.975 billion, representing roughly 2% to 6% growth, and adjusted EBITDA between $405 million and $435 million. Management expects ongoing free cash flow conversion above 40% of adjusted EBITDA, supported by a modest inventory build and capital expenditures of up to about $140 million.

Several factors will shape whether the company delivers on that outlook. The first is Hopewell, where key productivity investments are now complete and management's focus has shifted to execution and increasing production. Second, investors should watch demand signals in pharma and personal care, which have been the strongest growth engines, alongside any recovery in energy and resources end markets.

Currency is another consideration: recent dollar strength is expected to reduce fiscal 2027 sales by about $20 million to $25 million and adjusted EBITDA by $7 million to $10 million. Finally, pricing actions taken in the second half of fiscal 2026 will need to continue offsetting raw material inflation. With net leverage at 2.3x and total liquidity near $976 million, Ashland enters the new fiscal year with meaningful financial flexibility.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations